We are over the moon after last week’s defense from the now Dr, Léa Bernaleau!
Léa successfully defended her PhD thesis titled “Identification and characterization of new regulators in endolysosomal TLR biogenesis and signalling” on June 6th at the Department of Immunobiology of the University of Lausanne, after completing the private defense on May 6th 2025.
Her research focused on identifying novel molecular regulators involved in the biogenesis and signalling of endolysosomal Toll-like receptors (TLRs), which are critical for innate immunity and play a key role in autoimmune diseases. Her work provides new insights into the regulation of the TLR7/9–IRF5 pathway, including a deeper understanding of the SLC15A4–TASL complex and the discovery of a new regulator, CCDC134. These findings offer valuable perspectives on antiviral defense and the pathogenesis of systemic lupus erythematosus (SLE), and pave the way for novel targeted therapeutics.
The Rebsamen Lab warmly congratulates Léa and wishes her all the best for the next steps in her scientific journey! We couldn’t be more proud!
Congratulations Léa !!
To know more, check out these publications that are part of her thesis work:
- SLC15A4 controls endolysosomal TLR7–9 responses by recruiting the innate immune adaptor TASL
- A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity
- The TLR7/9 adaptors TASL and TASL2 mediate IRF5-dependent antiviral responses and autoimmunity in mouse
- CCDC134 controls TLR biogenesis through the ER chaperone Gp96
No responses yet